Harvard Clinical and Translational Science Center

哈佛临床和转化科学中心

• 批准号: 8721083
• 负责人: Lee Marshall Nadler
• 金额: $ 113.12万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8721083
• 关键词: Achievement; Address; Biological Markers; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Commit; Communities; Coupled; Education; Environment; Future; Goals; Health; Healthcare; Home environment; Human; Human Experimentation; Incentives; Institution; Instruction; Investigation; Methodology; Participant; Pathway interactions; Patients; Prevention; Research Infrastructure; Research Personnel; Research Training; Resolution; Resources; Safety; Schools; Science; Services; Speed; Strategic Planning; Structure; Therapeutic; Training; Training and Education; Transcend; Translating; Translational Research; Vision; Work; career development; catalyst; cost; improved; innovation; medical schools

Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a "One Harvard" community and culture committed to improving health. RELEVANCE (See instructions): The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

哈佛催化剂已经超越了历史、企业和文化长期强加的界限 哈佛大学及其17个附属学术医疗中心(AHC)的独立性将带来跨学科 研究人员一起协作并组成团队，进行临床和转化性(CT)研究。 今天，教育、资源和服务是共同规划、执行、广泛共享和评估的 在整个范围内提高质量、速度、安全、效率和成本的共同目标 CT研究。持续的CTSA认可，加上有机会成为重要的参与者 该联盟将使哈佛催化剂能够实施其愿景和战略计划。首先，我们将召开 来自我们11所学校和17所AHC的调查人员，以确定并优先考虑 CT研究。我们将帮助他们相互联系，组成跨学科的团队，然后 为他们提供机会、激励以及获得卓越教育和资源的途径 重视创新、协作和团队科学的环境。第二，我们将与我们的学校合作 以及AHC来构建和发展一种环境，以便快速高效地将发现转化为 改善人类健康。简单地说，哈佛催化剂努力成为召集者、连接者和催化剂 加快和提高CT研究的质量。为此，我们构建了我们的学术之家 创建一条教育、培训和职业发展的综合途径，并提供完整的 创新资源和服务，以解决已查明的差距和调查人员的需求。在五年内，我们的 成就将包括：1)所有CT的未来团队领导的持续、可持续、强大的渠道 2)实施SHRINE-CT，同时解决监管障碍，以使 研究人员快速识别、联系特定患者并使其参与跨机构和 在整个联合体中；3)建立一个专家团队，以减少以下障碍 参与并参与人体实验，从而增长和多样化了 进行CT研究的调查人员；4)基础设施，为所有CT调查人员提供访问 他们在工作最好的地方进行人类临床研究所需的资源；以及5)系统化 调查创新方法，以激励、组建和培养团队创造新的预防措施； 生物标志物和治疗学。这些成果将继续推动CT研究的转型 哈佛大学的目标是催生致力于改善健康的“同一个哈佛”社区和文化。 相关性(请参阅说明)： 哈佛临床和转化科学中心支持一个学术之家，创建一个 哈佛医学院及其合作机构的综合研究和培训环境 以改善人类健康。它提供和/或创建对资源和服务的访问权限，以支持 跨整个临床和转化性研究的临床研究步骤，并促进 翻译研究队伍的培训和职业发展。